about
Motivational interviewing: relevance in the treatment of rheumatoid arthritis?Components of treatment delay in rheumatoid arthritis differ according to autoantibody status: validation of a single-centre observation using national audit data.Differences in disease phenotype and severity in SLE across age groups.Patient involvement in rheumatology outpatient service design and delivery: a case study.Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid ArthritisDrug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with speciaVenous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.Changing clinical patterns in rheumatoid arthritis management over two decades: sequential observational studies.Is there a role of synovial biopsy in drug development?The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics RegisterA large two-centre study in to rates of influenza and pneumococcal vaccination and infection burden in rheumatoid arthritis in the UK.Smoking and common mental disorders in patients with chronic conditions: An analysis of data collected via a web-based screening system.Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general populationRisk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.Optimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction of >1.2 sufficient?The first national clinical audit for rheumatoid arthritis.Diagnostic yield of FDG-PET/CT in fever of unknown origin: a systematic review, meta-analysis, and Delphi exercise.Extreme elevation of ferritin and creatine kinase in primary infection with HIV-1.Achievement of NICE quality standards for patients with new presentation of inflammatory arthritis: observations from the National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis.The spectrum of early rheumatoid arthritis practice across the globe: results from a multinational cross sectional survey.Patient- and clinician-reported outcomes for patients with new presentation of inflammatory arthritis: observations from the National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis.The ying and yang of fever in rheumatic disease.Managing varicella zoster virus contact and infection in patients on anti-rheumatic therapy.A population study of the reported incidence of native joint septic arthritis in the United Kingdom between 1998 and 2013.Recipients' and providers' perspectives of obesity and potential barriers to weight management programmes in patients with Rheumatoid Arthritis (RA): a qualitative study.Investigation of rheumatoid arthritis genetic susceptibility markers in the early rheumatoid arthritis study further replicates the TRAF1 association with radiological damage.Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?Pulmonary Sarcoidosis in a patient with Multiple Sclerosis on daclizumab monotherapy.Polypharmacy and Unplanned Hospitalizations in Patients with Rheumatoid Arthritis.Response to: 'Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?' by Nocturne et al.Delivering future clinical trials in rheumatology.The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA.Twitter, #alternativefacts, careless whispers and Rheumatology.Predictors of objective cough frequency in pulmonary sarcoidosis.Depressive symptoms, pain and disability for adolescent patients with juvenile idiopathic arthritis: results from the Childhood Arthritis Prospective Study.Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.Rheumatoid arthritis - an update for general dental practitioners.Hydroxychloroquine use: the potential impact of new ocular screening guidelines.Patients' and carers' views and expectations about intensive management for moderate rheumatoid arthritis: a qualitative study.
P50
Q26777919-8F305032-D05C-4811-B965-9D9785184C28Q31112066-3ECAED65-9B2E-4CA3-A840-2B6AF8927FF0Q33431990-9C5AAFA0-1822-4DA0-946B-E216C2442A71Q33693177-586EB5C5-008B-4D07-86E0-267F2C926478Q33731716-E91D716E-8B86-43E3-AF69-7F9C8B22E9DBQ34081925-0CEB6D50-99E2-4FE4-B478-1485E7E238D2Q35018415-FED9BBDB-E8D9-45A1-AF6C-F44008F89EB0Q35200354-27ECDA04-7752-467A-B058-C43D6491A7E3Q35906327-4DEABA12-2EDB-461A-A3DD-50EB31B470C4Q35994130-D1F7A7BE-9764-459B-97D0-F801AF74AF08Q36020193-EAA4E2D3-E960-422F-AB2D-28356FC7F9B9Q36095259-BBFB96B6-2884-49AB-B16D-A87AF88E23FEQ36301331-E4B801D2-0351-4D6A-968B-21AD7895A153Q36464357-C72C18AB-98E1-410E-861D-641228F50553Q36679750-11B62712-76D5-426C-A0BD-57506221F9DDQ37010967-E56ACC84-BC46-4FCB-A500-8CCDF07E2143Q37087708-3E570767-4574-42E3-B828-F7193BC0ED92Q38733366-769CD076-0F13-4DE2-9FE3-4AB1B54364FBQ38886610-4DE6FE7D-1505-4E72-A78C-17D108954DA4Q38970157-F3AFC097-9BEE-4B37-80CF-CEF70E351F78Q38992551-F2F6669C-DB26-43F9-9EEA-8167ABB9BDF9Q39330884-CAF28896-82EB-4F1D-95E3-02CD4D5EF5A6Q40153534-257D4429-6787-4692-B445-D5F1BF3518D8Q40175407-36C29B13-6C77-43C2-B5F3-E6E682C131FAQ40537125-A4EC2005-0865-4E8A-BFC3-181B928BF6BEQ42672643-EE1DB9F6-8719-4F4B-A92A-7B79641397DEQ45004306-BC8C5D42-D7BD-4F81-A780-787D9A61B57DQ47102960-CF8CC1A4-5393-44F4-9A7E-2D323573D732Q47670548-BACF6B70-EA62-4C0B-801C-E280C8F635D3Q47670963-1286B69F-7EA4-49B7-8CEF-05A360B077E5Q48171928-7D806AB5-B201-4095-9F2C-3EBF31F51704Q48647281-53306154-F497-4711-9341-77FB0BD59E1FQ51019088-34AD9F5F-BE57-42E7-BCCF-8FAEDDDE887FQ51429452-C104C37E-F539-457D-B078-C2AF74A0274FQ51549569-07A1B77F-1F0B-4552-AA54-516923DE2BBFQ52561537-C1435803-C3A1-4085-89F4-33E786C38405Q52625078-B56D456D-CE5D-4368-8119-7BED046B88B8Q52810344-044E4596-71C5-4622-85FE-3F6B2507BC7CQ53116103-4017A42D-D147-4776-B0B3-7BD59709A83BQ53184861-F53B5E7E-0CDA-4D92-9924-166B1DF5B299
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
James B Galloway
@ast
James B Galloway
@en
James B Galloway
@es
James B Galloway
@nl
type
label
James B Galloway
@ast
James B Galloway
@en
James B Galloway
@es
James B Galloway
@nl
prefLabel
James B Galloway
@ast
James B Galloway
@en
James B Galloway
@es
James B Galloway
@nl
P106
P21
P31
P496
0000-0002-1230-2781